Nelfinavir Mesylate (Viracept) Access for HIV-Positive Patients with Low CD4 Count
Nelfinavir mesylate
Blood-Borne Infections+13
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
The study focuses on providing a drug called nelfinavir mesylate (Viracept) to HIV positive patients. This is specifically for those who can't take the three commercially available protease inhibitors due to various reasons like failure, intolerance, or contraindication. The study also targets patients with a CD4 cell count of 50 or less. The goal is to help these patients manage their condition better, especially since they have limited treatment options. The study also aims to gather more information on the safety of using nelfinavir mesylate (Viracept). Participants in the study will receive nelfinavir mesylate (Viracept) as part of their treatment. The study will monitor the safety of the drug and its effects on the participants. It's important to note that participants who can't take indinavir and/or ritonavir due to intolerance, contraindication, or prior failure are now eligible for the Viracept Program.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 13 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location